Enzyme source effects on CYP2C9 kinetics and inhibition

Drug Metabolism and Disposition

Volumn 34, Issue 11, 2006, Pages 1903-1908

  Kumar, Vikas ^a   Rock, Dan A ^b   Warren, Chad J ^b   Tracy, Timothy S ^a   Wahlstrom, Jan L ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZBROMARONE; CYTOCHROME P450 2C9; CYTOCHROME P450 REDUCTASE INHIBITOR; DICLOFENAC; ENZYME INHIBITOR; FLURBIPROFEN; FLUVOXAMINE; GEMFIBROZIL; IBUPROFEN; INDOMETACIN; KETOCONAZOLE; MICONAZOLE; MICROSOME ENZYME; PHENYTOIN; PIROXICAM; RECOMBINANT ENZYME; SULFAPHENAZOLE; TOLBUTAMIDE; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PURIFICATION; ENZYME SUBSTRATE COMPLEX; HUMAN; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

EID: 33751085910     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.010249     Document Type: Article

References (16)

1. Crespi CL and Penman BW (1997) Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 43:171-188.
2. Hemeryck A, De Vriendt C, and Belpaire FM (1999) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. Eur J Clin Pharmacol 54:947-951.
3. Hummel MA, Locuson CW, Gannett PM, Rock DA, Mosher CM, Rettie AE, and Tracy TS (2005) CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol 68:644-651.
4. Hutzler JM, Wienkers LC, Wahlstrom JL, Carlson TJ, and Tracy TS (2003) Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch Biochem Biophys 410:16-24.
5. Northrup DB (1998) On the meaning of Km and Vmax/Km in enzyme kinetics. J Chem Educ 75:1153-1157.
6. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
7. Rettie AE and Jones JP (2005) Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45:477-494.
8. Schrag ML and Wienkers LC (2000) Topological alteration of the CYP3A4 active site by the divalent cation Mg(2+). Drug Metab Dispos 28:1198-1201.
9. Shaw PM, Hosea NA, Thompson DV, Lenius JM, and Guengerich FP (1997) Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5. Arch Biochem Biophys 348:107-115.
10. Shimada T, Mernaugh RL, and Guengerich FP (2005) Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5) enzymes. Arch Biochem Biophys 435:207-216.
11. Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ, and Korzekwa KR (1995) Role of cytochrome P450 2C9 and an allelic variant in the 4′- hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol 49:1269-1275.
12. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblatt DJ (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504.
13. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660.
14. Wester MR, Lasker JM, Johnson EF, and Raucy JL (2000) CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos 28:354-359.
15. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208.
16. Zhang Z, Li Y, Shou M, Zhang Y, Ngui JS, Stearns RA, Evans DC, Baillie TA, and Tang W (2004) Influence of different recombinant systems on the cooperativity exhibited by cytochrome P4503A4. Xenobiotica 34:473-486.